PharmaMar Signs Commercialization and Distribution License Agreement for Aplidin (Plitidepsin) with Megapharm Ltd in Israel
January 02, 2018 at 05:00 pm IST
Share
PharmaMar has announced a commercialization and distribution license agreement with Megapharm Ltd. for the marine-derived anticancer drug Aplidin (plitidepsin) in Israel and the territory known as the Palestinian Authority. According to the agreement Megapharm will register Aplidin on behalf of PharmaMar and distribute the compound in both regions. PharmaMar will retain exclusive production rights and will supply the finished product for clinical and commercial use. Aplidin is PharmaMars second most advanced anticancer drug which is currently under development for the treatment of multiple myeloma and angioimmunoblastic T-cell lymphoma. The Company announced in March 2016 that plitidepsin has shown positive results in a pivotal Phase III clinical trial (ADMYRE) for multiple myeloma.
Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Companyâs product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.